Four Organizations Unite to Launch the "Pharmaceutical Sovereignty Patients and Consumers Coalition"

Patient and consumer organizations have called for measures to guarantee patients' right to information and freedom of choice, demanding a reduction in the prices of generic drugs and the enactment of a special law on non-reimbursed medical services.


The Association for Pharmaceutical Sovereignty Patients and Consumers is holding its inaugural press conference on the 24th at the Korea Consumer Federation in Yongsan-gu, Seoul. The Association for Pharmaceutical Sovereignty Patients and Consumers.

The Association for Pharmaceutical Sovereignty Patients and Consumers is holding its inaugural press conference on the 24th at the Korea Consumer Federation in Yongsan-gu, Seoul. The Association for Pharmaceutical Sovereignty Patients and Consumers.

View original image

The Korea Consumer Federation, Korean Alliance of Patients Organization, Consumers Korea, and Korea Alliance of Patients with Rare Diseases held a press conference at the Korea Consumer Federation in Seoul on the 24th and officially announced the launch of the "Pharmaceutical Sovereignty Patients and Consumers Coalition."


These organizations pointed out, "Even as the range of pharmaceuticals diversifies and non-reimbursed medical services expand, citizens find it difficult to know exactly what treatments, which drugs, and at what cost they are choosing," adding, "Information is closed off, choices are restricted, and responsibility is shifted to citizens."


They also criticized the government's recent proposal to reform the drug pricing system, stating, "It is difficult to understand why citizens' health insurance premiums should be used to support private pharmaceutical companies' research and development (R&D)," and argued, "For the past 25 years, high generic drug prices have been compensated with citizens' health insurance premiums, yet new drug development achievements have been minimal."


Regarding non-reimbursed medical services, they stated, "While the government and the medical community know whether there is sufficient medical evidence to justify the high costs, patients and consumers do not have access to that information," emphasizing, "If cost-effectiveness is proven, the information should be released and the service should be covered by insurance; if effectiveness is unclear, citizens should be able to exercise their right to refuse such services."


The coalition presented ten key demands: ▲Reducing generic drug prices and improving the rebate-driven competitive structure ▲Full public disclosure of bioequivalence test results for generics ▲Mandatory Drug Utilization Review (DUR), including injectables and non-reimbursed items ▲Mandatory labeling of injectables on prescriptions ▲Mandatory indication of drug prices and expected out-of-pocket costs on prescriptions ▲Enactment of a special law on non-reimbursed medical service management ▲Establishment of a patient and consumer-led center to monitor drug efficacy and non-reimbursed services ▲Separation of over-the-counter drug display areas and cash registers within pharmacies ▲Creation of a reporting center for excessive promotion of drugs and non-reimbursed services ▲Expansion of over-the-counter household medicine items sold in convenience stores.



The coalition plans to actively pursue activities such as bioequivalence test sampling monitoring, holding a National Assembly public hearing on revising the Pharmaceutical Affairs Act, organizing a public hearing on enacting a special law on non-reimbursed medical service management, and launching a nationwide petition campaign.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing